KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer

Future Oncology

Volumn 11, Issue 13, 2015, Pages 1919-1929

  Camaj, Peter ^a,b,c   Primo, Stefano ^a   Wang, Yan ^a,c   Heinemann, Volker ^a,b   Zhao, Yue ^a,c   Laubender, Ruediger Paul ^b,d   Stintzing, Sebastian ^a,b   Giessen Jung, Clemens ^a,b   Jung, Andreas ^b,d   Gamba, Sebastian ^a   Bruns, Christiane Josephine ^a,b,c   Modest, Dominik Paul ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

colorectal cancer; ELK; KRAS; MAPK pathway; regorafenib

Indexed keywords

K RAS PROTEIN; REGORAFENIB; CARBANILAMIDE DERIVATIVE; KRAS PROTEIN, HUMAN; PROTEIN P21; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CELL MUTANT; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; GENE MUTATION; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HUMAN; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EXONS; HUMANS; MICE; MUTATION; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS P21(RAS); PYRIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84936931939     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.97     Document Type: Article

References (21)

1. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 303-312 (2013).
2. Mross K, Frost A, Steinbild S et al. A Phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin. Cancer Res. 18(9), 2658-2667 (2012).
3. Schmieder R, Hoffmann J, Becker M et al. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int. J. Cancer J. 135(6), 1487-1496 (2014).
4. Schultheis B, Folprecht G, Kuhlmann J et al. Regorafenib in combination with FOLFOX or FOLFIRI as first-or second-line treatment of colorectal cancer: results of a multicenter, Phase Ib study. Ann. Oncol. 24(6), 1560-1567 (2013).
5. Strumberg D, Scheulen ME, Schultheis B et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a Phase I study. Br. J. Cancer 106(11), 1722-1727 (2012).
6. Wilhelm SM, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129(1), 245-255 (2011).
7. Douillard J-Y, Siena S, Cassidy J et al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28(31), 4697-4705 (2010).
8. Douillard J-Y, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369(11), 1023-1034 (2013).
9. Van Cutsem E, Köhne C-H, Láng I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29(15), 2011-2019 (2011).
10. Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, Phase 3 trial. Lancet Oncol. 15(10), 1065-1075 (2014).
11. Modest DP, Stintzing S, Laubender RP et al. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anticancer Drugs 22(9), 913-918 (2011).
12. Modest DP, Jung A, Moosmann N et al. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. Int. J. Cancer 131(4), 980-986 (2012).
13. De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16), 1812-1820 (2010).
14. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J. Clin. Oncol. 30(29), 3570-3577 (2012).
15. Modest DP, Camaj P, Heinemann V et al. KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. J. Cancer Res. Clin. Oncol. 139(6), 953-961 (2013).
16. Messner I, Cadeddu G, Huckenbeck W et al. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. J. Cancer Res. Clin. Oncol. 139(2), 201-209 (2013).
17. Konishi H, Karakas B, Abukhdeir AM et al. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res. 67(18), 8460-8467 (2007).
18. Khan IF, Hirata RK, Russell DW. AAV-mediated gene targeting methods for human cells. Nat. Protoc. 6(4), 482-501 (2011).
19. Di Nicolantonio F, Arena S, Gallicchio M et al. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc. Natl Acad. Sci. USA 105(52), 20864-20869 (2008).
20. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol. Res. Pract. 205(12), 858-862 (2009).
21. Piscazzi A, Costantino E, Maddalena F et al. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 97(6), E898-906 (2012).